Search by Drug Name or NDC
NDC 71610-0177-42 Jardiance 25 mg/1 Details
Jardiance 25 mg/1
Jardiance is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Aphena Pharma Solutions - Tennessee, LLC. The primary component is EMPAGLIFLOZIN.
MedlinePlus Drug Summary
Empagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Empagliflozin is also used to reduce the risk of stroke, heart attack, or death in people who have type 2 diabetes along with heart and blood vessel disease. Empagliflozin is also used in adults with heart failure to reduce the risk of needing to be hospitalized and death due to heart and blood vessel disease. Empagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. Empagliflozin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 71610-0177-42Last Updated: 02/19/2023
MedLinePlus Full Drug Details: Empagliflozin
Product Information
NDC | 71610-0177 |
---|---|
Product ID | 71610-177_75491ff1-aa83-4d04-89ad-1137b2838e7a |
Associated GPIs | 27700050000320 |
GCN Sequence Number | 072489 |
GCN Sequence Number Description | empagliflozin TABLET 25 MG ORAL |
HIC3 | C4D |
HIC3 Description | ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT2(SGLT2) INH |
GCN | 36723 |
HICL Sequence Number | 041217 |
HICL Sequence Number Description | EMPAGLIFLOZIN |
Brand/Generic | Generic |
Proprietary Name | Jardiance |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Empagliflozin |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET, FILM COATED |
Route | ORAL |
Active Ingredient Strength | 25 |
Active Ingredient Units | mg/1 |
Substance Name | EMPAGLIFLOZIN |
Labeler Name | Aphena Pharma Solutions - Tennessee, LLC |
Pharmaceutical Class | Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA204629 |
Listing Certified Through | 2024-12-31 |
Package
NDC 71610-0177-42 (71610017742)
NDC Package Code | 71610-177-42 |
---|---|
Billing NDC | 71610017742 |
Package | 1800 TABLET, FILM COATED in 1 BOTTLE (71610-177-42) |
Marketing Start Date | 2022-12-09 |
NDC Exclude Flag | N |
Pricing Information | N/A |